Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M(1) positive allosteric modulators.

[1]  M. Seager,et al.  Identification of amides as carboxylic Acid surrogates for quinolizidinone-based m1 positive allosteric modulators. , 2012, ACS medicinal chemistry letters.

[2]  William J Ray,et al.  Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. , 2011, Journal of medicinal chemistry.

[3]  M. Seager,et al.  Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators. , 2010, ACS medicinal chemistry letters.

[4]  M. Quirk,et al.  A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.

[5]  Craig W. Lindsley,et al.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.

[6]  A. Deutch,et al.  Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.

[7]  Christopher J Langmead,et al.  Muscarinic acetylcholine receptors as CNS drug targets. , 2008, Pharmacology & therapeutics.

[8]  C. Strader,et al.  Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. , 2001, Farmaco.

[9]  D. Witty.  27th National Medicinal Chemistry Symposium. , 2000, IDrugs : the investigational drugs journal.

[10]  Changiz Geula,et al.  Abnormalities of neural circuitry in Alzheimer's disease , 1998, Neurology.

[11]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[12]  A. Levey.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Bonner.  The molecular basis of muscarinic receptor diversity , 1989, Trends in Neurosciences.

[14]  D. Chan.  American Chemical Society - 33rd National Medicinal Chemistry Symposium (NMCS), Tucson, Arizona, USA - May 20-23, 2012 , 2012, Drugs of the Future.

[15]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.